compounding semaglutide fda enforcement news today The is drawing a harder line on compounded weight loss drug marketing. In the May–June 2026 issue of Dispense Times, this article breaks down key violations cited in recent FDA FDA cracks down on 'misleading'

These additional risks layer on top of the inherent risks of the molecule itself

To minimize treatment interruptions due to adverse reactions, subsequent Phase III clinical trials may adopt a more gradual dose-escalation strategy to reduce the incidence and severity of gastrointestinal discomfort and other adverse events, thereby enhancing patient tolerance and adherence to the medication

Readers are encouraged to verify all details directly with brand customer service and their healthcare provider before making decisions

Retatrutides Phase 2 data also demonstrated robust improvements in blood pressure, fasting glucose, and triglycerides

Pregnancy and breastfeeding: These medications are not recommended for use during pregnancy or breastfeeding when prescribed for weight management